Showing 831-840 of 1116 results for "".
- Industry Opticianry Organizations Announce Merger at Vision Expo Easthttps://modernod.com/news/industry-opticianry-organizations-announce-merger-at-vision-expo-east/2482169/The Opticians Association of America [OAA], and the National Federation of Opticianry Schools [NFOS], have completed a merger to create the "United Opticians Association [UOA]," a model Opticianry Association representing over 80,000 opticians and contact lens professionals throughout N
- Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Boardhttps://modernod.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding N
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Atia Vision Announces Presentation of First-In-Human Results with OmniVu IOL System at ASCRShttps://modernod.com/news/atia-vision-announces-presentation-of-first-in-human-results-with-their-novel-intraocular-lens-at-ascrs/2481598/Atia Vision announced the first clinical data on the patented OmniVu IOL System will be presented at the 2023 Annual Meeting of the American Society of Cataract Refractive Surgery (ASCRS) in San Diego, California. First-in-human findings will be shared by&n
- GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from Phase 1/2 Trial of Optogenetic Treatment Candidate for RPhttps://modernod.com/news/gensight-biologics-announces-1-year-safety-data-and-efficacy-signals-from-phase-12-trial-of-optogenetic-treatment-candidate-for-rp/2481413/GenSight Biologics announced favorable safety data and encouraging efficacy signals at 1 year post-gene therapy administration for the PIONEER phase 1/2 clinical trial evaluating GS030 for the treatment of retinitis pigmentosa (RP) in 9 patients, with a follow-up up to 4 years (n=1).
- GenSight Biologics Announces Publication of Indirect Comparison of Lumevoq Versus Natural History in ND4-LHON Patientshttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-of-lumevoq-versus-natural-history-in-nd4-lhon-patients/2481299/GenSight Biologics announced the publication of a peer-reviewed article in the journal Ophthalmology and Therapy highlighting updated efficacy results from a pooled analysis of four phase 3 studies showing an improvement in visual acuity in ND4-LHON patients treated with&n
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n
- Oyster Point Pharma to Present New Analyses at ARVO 2022https://modernod.com/news/oyster-point-pharma-to-present-new-analyses-at-arvo-2022/2480807/Oyster Point Pharma announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4. “We are pleased to be presenting new analyses of the pivotal trial data of Tyrvaya&n
- FDA Approves Staar Surgical's EVO Visian Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-announces-fda-approval-of-evo-visian-implantable-collamer-lenses/2480724/Staar Surgical Company announced that the FDA has granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. "Following FDA approval, prospective patients in the U.S. and their doctors may n